Data from the EMBARK trial suggest patients may have functional improvements taking the gene therapy between 8 and 9 years old.

After sweeping cuts to US federal health agencies, the elimination of a committee responsible for recommending newborn ...

Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...